合成血液代用品市场－全球产业规模、份额、趋势、机会及预测（依产品、应用、来源、成分、地区及竞争格局划分），2021-2031年

全球合成血液替代品市场预计将从 2025 年的 1,039 万美元成长到 2031 年的 1,858 万美元，复合年增长率为 10.17%。

这个领域主要包括合成疗法，特别是基于血红蛋白的氧载体和全氟碳乳剂，旨在模拟天然血液的氧气运输能力。其成长的主要驱动力是捐血血液固有的物流限制，例如保质期有限以及持续的全球供不应求，这些都使得寻找稳定的替代方案变得迫切。这些根本性因素并非暂时的趋势，而是旨在解决整个医疗保健系统中存在的各种不平等问题。例如，美国红十字会报告称，2024年7月全国血液库存下降了超过25%，凸显了对可靠的合成解决方案的巨大商业性需求。

然而，严格的临床安全监管壁垒严重阻碍了市场成长。主要障碍在于不良生理反应的发生，例如血管收缩和肾毒性，这些反应历来会导致后期临床试验的终止。因此，证明其安全性与人血相当的挑战限制了其广泛的商业性应用。对于那些希望将产品从实验研究阶段推进到实际医疗应用阶段的製造商而言，解决这些毒性问题是至关重要的。

市场驱动因素

全球捐血长期短缺是推动全球合成血液替代品市场发展的主要因素。医疗系统难以维持日常和紧急医疗所需的血液库存。而完全依赖自愿捐血的物流脆弱性，又因季节性波动和公共卫生危机等因素而加剧了这项短缺。因此，血液采集量与临床需求之间日益扩大的差距迫使医院寻求可储存的合成替代品，以摆脱对人类捐血者的依赖。英国国家医疗服务体系（NHS）血液和移植中心2025年6月的一项分析凸显了这一关键缺口，该分析发现，英格兰每年需要超过20万名捐血者才能满足不断增长的需求，这凸显了非生物输血方案的紧迫性。

此外，军事和国防领域的战略需求是市场创新的关键驱动力，其中无需低温运输储存的氧载体的研发尤为重要。国防机构正积极资助研发在敌对作战环境中治疗出血性休克的实用解决方案，因为在这些环境中，传统的输血在后勤上难以实现。这种作战需求正推动对冻干人工细胞等技术的巨额投资。例如，UM Ventures在2025年1月报告称，生物技术开发商Callocyte获得了美国国防部和国立卫生研究院1700万美元的津贴，用于进一步开发其ErythroMer技术。同样，在2025年，宾州州立大学的研究团队获得了270万美元的津贴，用于推进模拟人类红血球的合成血液替代品的研发。

市场挑战

严格的临床安全监管环境是全球合成血液替代品市场商业性成长的主要障碍。製造商始终难以证明其基于血红蛋白的氧载体和全氟碳乳剂与天然人血一样安全。许多后期临床试验因反覆出现严重的生理不利事件（例如血管收缩和肾毒性）而被迫中止。由于监管机构采用非劣效性标准，这些安全漏洞导致产品无法获得强制性核准，从而有效地阻碍了其从实验原型到可上市医疗解决方案的转换。

天然血液输注设定的极高安全标准进一步加剧了监管瓶颈。这些标准规定了合成替代血液必须达到的门槛，而严格的安全统计标准使得即使是毒性较小的合成替代血液也难以获得核准。例如，根据血液和生物疗法促进协会（AABB）的数据，2024年的主动监测数据显示，红血球输注导致严重併发症（例如输血相关性急性肺损伤（TRALI））的发生率仅为每10,000例输血0.17例。如果合成替代血液未能展现出类似的低风险特性，则会导致监管机构拒绝核准上市，从而直接阻碍该行业的扩张。

市场趋势

开发用于降低毒性的包封血红蛋白囊泡是一项重要的发展趋势，它解决了长期以来阻碍产业发展的安全问题。与会导致严重血管收缩和肾损伤的传统游离血红素製剂不同，这种方法专注于将血红蛋白包封在脂质双层膜内，模拟天然红血球的结构稳定性。透过保护血管内皮免受血红蛋白的直接接触，生产商可以有效减少先前阻碍监管部门核准的不良生理反应。这项结构创新目前正从理论研究走向人体临床试验。例如，MedEdge MEA在2025年5月报道称，奈良医科大学已启动一项临床试验，向志愿者註射100至400毫升血红蛋白囊泡，以检验在紧急输血中的安全性。

同时，转向重组和基因改造血红蛋白来源正在改变供应链，最大限度地减少对有限供体来源材料的依赖。利用合成生物学和精准发酵技术，研发人员正逐步摆脱从过期的人血或牛血中提取血红蛋白的做法，转而在受控的实验室环境中生产生物同源蛋白。此举消除了与生物采集相关的病原体传播风险和供应限制，并实现了药用级血红蛋白的大规模生产，以满足全球创伤护理需求。例如，2025年10月，UM Ventures宣布Crycea公司签署了一项独家许可协议，授权其使用专有的生物合成血红蛋白技术，从而实现不依赖人血或动物血成分的氧载体的大规模生产。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球合成血液代用品市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（血红素基氧载体（HBOC）、全氟碳乳剂（PFC）、干细胞衍生红血球、其他）
  • 依应用领域（心血管疾病、恶性肿瘤、创伤、新生儿疾病、器官移植、孕产妇疾病、其他）
  • 依来源（人类血液来源、微生物来源的重组红血球、合成聚合物、干细胞、其他）
  • 依成分（红血球代用品、血小板代用品、血浆代用品）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美合成血液替代品市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲合成血液代用品市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区合成血液代用品市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲合成血液替代品市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲合成血液替代品市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球合成血液代用品市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Aurum Biosciences Ltd
• Hemarina SA
• Hemoglobin Oxygen Therapeutics LLC
• SpheriTech Ltd
• Kalocyte, Inc.
• OPKO Health, Inc.
• Prolong Pharmaceuticals, LLC
• VisusMed Medical Center
• Boston Pharmaceuticals, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Synthetic Blood Substitute Market is projected to expand from USD 10.39 Million in 2025 to USD 18.58 Million by 2031, registering a CAGR of 10.17%. This sector consists of artificial therapeutics, primarily hemoglobin-based oxygen carriers and perfluorocarbon emulsions, designed to replicate the oxygen-transport capabilities of natural blood. Growth is chiefly driven by the inherent logistical limitations of donor blood, such as restricted shelf-life, and persistent global supply shortages that generate an urgent need for stable alternatives. These foundational drivers address systemic healthcare gaps rather than transient trends; for example, the American Red Cross reported a national blood inventory decline of over 25% in July 2024, underscoring the critical commercial need for reliable synthetic solutions.

However, market growth is significantly hindered by rigorous regulatory barriers related to clinical safety. The primary obstacle remains the occurrence of adverse physiological reactions, including vasoconstriction and renal toxicity, which have historically halted late-stage clinical trials. Consequently, the challenge of proving a safety profile equivalent to human blood limits widespread commercial adoption. Resolving these toxicity issues stands as the definitive hurdle for manufacturers seeking to advance products from experimental research into viable medical applications.

Market Driver

The chronic global scarcity of donor blood serves as the main catalyst for the Global Synthetic Blood Substitute Market, as healthcare systems struggle to sustain inventories sufficient for routine and emergency care. This shortage is intensified by the logistical vulnerability of relying exclusively on voluntary donations, which face frequent disruptions due to seasonal changes and public health crises. As a result, the expanding disparity between collection volumes and clinical needs compels hospitals to pursue shelf-stable artificial alternatives that remove dependence on human donors. Highlighting this critical gap, an analysis by NHS Blood and Transplant in June 2025 identified an annual shortfall of over 200,000 donors required to satisfy rising demand in England, emphasizing the urgent need for non-biological transfusion options.

Furthermore, strategic requirements from the military and defense sectors act as a significant accelerator for market innovation, with a priority on developing oxygen carriers that function without cold-chain storage. Defense agencies are actively financing research into field-ready solutions designed to treat hemorrhagic shock in harsh combat settings where traditional transfusions are logistically unfeasible. This operational necessity channels substantial investment toward technologies such as freeze-dried artificial cells. For instance, UM Ventures reported in January 2025 that biotech developer KaloCyte received $17 million in grants from the Department of Defense and National Institutes of Health to progress its ErythroMer technology. Similarly, in 2025, a research team at Penn State University secured a $2.7 million grant to advance synthetic blood substitutes mimicking human red blood cells.

Market Challenge

The rigorous regulatory landscape concerning clinical safety constitutes the primary obstacle to the commercial growth of the Global Synthetic Blood Substitute Market. Manufacturers face consistent difficulties in proving that hemoglobin-based oxygen carriers and perfluorocarbon emulsions can replicate the safety profile of natural human blood. The repeated incidence of severe adverse physiological effects, such as vasoconstriction and renal toxicity, has resulted in the cessation of numerous late-stage clinical trials. Since regulatory authorities enforce a standard of non-inferiority, these safety shortcomings prevent products from securing essential approvals, effectively halting the progression from experimental prototypes to marketable medical solutions.

This regulatory bottleneck is exacerbated by the exceptionally high safety benchmarks set by natural blood transfusions, which define the standards synthetic alternatives must achieve. The statistical criteria for safety are exacting, complicating the approval process for engineered substitutes that demonstrate even minimal toxicities. For example, according to the Association for the Advancement of Blood & Biotherapies (AABB), active surveillance data in 2024 indicated that the rate of serious complications like Transfusion-Related Acute Lung Injury (TRALI) for red blood cells was as low as 0.17 per 10,000 transfusions. The failure of synthetic candidates to exhibit a similarly low risk profile compels regulators to deny market authorization, thereby directly stifling industry expansion.

Market Trends

The development of encapsulated hemoglobin vesicles to mitigate toxicity is a pivotal trend addressing the safety failures that have historically impeded industry advancement. Unlike earlier free-hemoglobin solutions that induced severe vasoconstriction and renal injury, this approach focuses on enclosing hemoglobin within lipid bilayer membranes to replicate the structural stability of natural red blood cells. By protecting the vascular lining from direct hemoglobin contact, manufacturers are effectively lowering the adverse physiological reactions that previously hindered regulatory success. This structural innovation is now moving from theoretical research to human trials; for instance, MedEdge MEA reported in May 2025 that Nara Medical University launched a clinical trial administering 100 to 400 milliliters of these hemoglobin vesicles to volunteers to verify their safety for emergency transfusions.

Concurrently, the shift toward recombinant and genetically modified hemoglobin sources is transforming the supply chain by minimizing dependence on finite donor-derived raw materials. Utilizing synthetic biology and precision fermentation, developers are transitioning away from extracting hemoglobin from expired human or bovine blood to producing bio-identical proteins in controlled laboratory settings. This move eradicates the risks of pathogen transmission and supply constraints linked to biological collection, facilitating the scalable, pharmaceutical-grade production necessary to meet global trauma needs. Illustrating this progress, UM Ventures announced in October 2025 that Chrysea finalized an exclusive licensing agreement to deploy its biosynthetic hemoglobin technology, enabling the mass manufacture of oxygen carriers without relying on human or animal blood components.

Key Market Players

• Aurum Biosciences Ltd
• Hemarina SA
• Hemoglobin Oxygen Therapeutics LLC
• SpheriTech Ltd
• Kalocyte, Inc.
• OPKO Health, Inc.
• Prolong Pharmaceuticals, LLC
• VisusMed Medical Center
• Boston Pharmaceuticals, Inc

Report Scope

In this report, the Global Synthetic Blood Substitute Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Synthetic Blood Substitute Market, By Product

• Hemoglobin-Based Oxygen Carriers (HBOCs)
• Perfluorocarbon Emulsions (PFCs)
• Stem Cell-Derived Red Blood Cells
• Others

Synthetic Blood Substitute Market, By Application

• Cardiovascular Diseases
• Malignant Neoplasma
• Injuries
• Neonatal Conditions
• Organ Transplant
• Maternal Condition
• Others

Synthetic Blood Substitute Market, By Source

• Human Blood
• Microorganism Based Recombinant HB
• Synthetic Polymers
• Stem Cells
• Others

Synthetic Blood Substitute Market, By Component

• Red Blood Cell Substitutes
• Platelet Substitutes
• Plasma Substitutes

Synthetic Blood Substitute Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Synthetic Blood Substitute Market.

Available Customizations:

Global Synthetic Blood Substitute Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Synthetic Blood Substitute Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Hemoglobin-Based Oxygen Carriers (HBOCs), Perfluorocarbon Emulsions (PFCs), Stem Cell-Derived Red Blood Cells, Others)
  • 5.2.2. By Application (Cardiovascular Diseases, Malignant Neoplasma, Injuries, Neonatal Conditions, Organ Transplant, Maternal Condition, Others)
  • 5.2.3. By Source (Human Blood, Microorganism Based Recombinant HB, Synthetic Polymers, Stem Cells, Others)
  • 5.2.4. By Component (Red Blood Cell Substitutes, Platelet Substitutes, Plasma Substitutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Synthetic Blood Substitute Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Source
  • 6.2.4. By Component
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Synthetic Blood Substitute Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Source
      • 6.3.1.2.4. By Component
  • 6.3.2. Canada Synthetic Blood Substitute Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Source
      • 6.3.2.2.4. By Component
  • 6.3.3. Mexico Synthetic Blood Substitute Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Source
      • 6.3.3.2.4. By Component

7. Europe Synthetic Blood Substitute Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Source
  • 7.2.4. By Component
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Synthetic Blood Substitute Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Source
      • 7.3.1.2.4. By Component
  • 7.3.2. France Synthetic Blood Substitute Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Source
      • 7.3.2.2.4. By Component
  • 7.3.3. United Kingdom Synthetic Blood Substitute Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Source
      • 7.3.3.2.4. By Component
  • 7.3.4. Italy Synthetic Blood Substitute Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Source
      • 7.3.4.2.4. By Component
  • 7.3.5. Spain Synthetic Blood Substitute Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Source
      • 7.3.5.2.4. By Component

8. Asia Pacific Synthetic Blood Substitute Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Source
  • 8.2.4. By Component
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Synthetic Blood Substitute Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Source
      • 8.3.1.2.4. By Component
  • 8.3.2. India Synthetic Blood Substitute Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Source
      • 8.3.2.2.4. By Component
  • 8.3.3. Japan Synthetic Blood Substitute Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Source
      • 8.3.3.2.4. By Component
  • 8.3.4. South Korea Synthetic Blood Substitute Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Source
      • 8.3.4.2.4. By Component
  • 8.3.5. Australia Synthetic Blood Substitute Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Source
      • 8.3.5.2.4. By Component

9. Middle East & Africa Synthetic Blood Substitute Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Source
  • 9.2.4. By Component
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Synthetic Blood Substitute Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Source
      • 9.3.1.2.4. By Component
  • 9.3.2. UAE Synthetic Blood Substitute Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Source
      • 9.3.2.2.4. By Component
  • 9.3.3. South Africa Synthetic Blood Substitute Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Source
      • 9.3.3.2.4. By Component

10. South America Synthetic Blood Substitute Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Source
  • 10.2.4. By Component
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Synthetic Blood Substitute Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Source
      • 10.3.1.2.4. By Component
  • 10.3.2. Colombia Synthetic Blood Substitute Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Source
      • 10.3.2.2.4. By Component
  • 10.3.3. Argentina Synthetic Blood Substitute Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Source
      • 10.3.3.2.4. By Component

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Synthetic Blood Substitute Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Aurum Biosciences Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Hemarina SA
• 15.3. Hemoglobin Oxygen Therapeutics LLC
• 15.4. SpheriTech Ltd
• 15.5. Kalocyte, Inc.
• 15.6. OPKO Health, Inc.
• 15.7. Prolong Pharmaceuticals, LLC
• 15.8. VisusMed Medical Center
• 15.9. Boston Pharmaceuticals, Inc

16. Strategic Recommendations

17. About Us & Disclaimer